TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03977844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical Assistance
Description: TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Technical Assistance
Description: TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning
Description: CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles \[48, 64\]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Resources (CR)
Description: The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Resources (CR)
Description: The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
Study: NCT04066192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A medically inert placebo medication will be used as described in the study arms.
Study: NCT04708626

Intervention type: OTHER
Intervention: Description and analysis
Description: Collection of clinical, laboratory and radiological data from medical records.

Intervention type: OTHER
Intervention: Description and analysis
Description: Collection of laboratory data.
Study: NCT03977844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Resources + eBT
Description: The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities \[65\]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app.
Study: NCT02973659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
Study: NCT00876109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
Study: NCT02973659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Study: NCT00786916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Study: NCT04840095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketones
Description: Sports supplement that is administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketones
Description: Sports supplement that is administered mid-scan.
Study: NCT00876109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
Study: NCT04840095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement is administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement is administered mid-scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement is administered mid-scan.
Study: NCT03813303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Administration of midazolam by anesthesiologist for sedation.
Study: NCT03515889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ideal Protein Weight Loss Method
Description: An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss
Description: This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute).
Study: NCT03813303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Administration of fentanyl by anesthesiologist for sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Administration of propofol by anesthesiologist for sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Administration of propofol by anesthesiologist for sedation.
Study: NCT02621905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sporanox
Description: At least 2 capsules twice a day for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lozanoc
Description: At least 2 capsules twice a day for 3 weeks
Study: NCT02174094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03711123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group metacognitive therapy
Description: 10 weekly Group session of 90 minutes duration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical management
Description: 10 weekly individual sessions With clinical management including guided self-help
Study: NCT00530023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiniMed Paradigm REAL-Time System
Description: MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
Study: NCT04468048

Intervention type: OTHER
Intervention: Music: Nada Himalaya performed by S. G. Sachchidananda
Description: Music: Nada Himalaya performed by S. G. Sachchidananda
Study: NCT04574362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: One 75mg orally disintegrating tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02700646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: standard care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: standard care
Study: NCT02162628

Intervention type: DEVICE
Intervention: Exair Prolapse Repair System

Intervention type: PROCEDURE
Intervention: Total Native Tissue Repair
Study: NCT04049994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uro-Vaxom
Description: Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study: NCT03055234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Treprostinil
Description: Extended-release oral tablet for TID administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for TID administration
Study: NCT00963664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
Study: NCT01761617

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga class once per week
Description: The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga class twice per week
Description: The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio.
Study: NCT02539472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
Study: NCT00668369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gradual immunosuppression drug withdrawal.
Description: Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
Study: NCT01072318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg
Study: NCT04420026

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Interact Active Tracker
Description: Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
Study: NCT01194297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: One dose of live attenuated influenza vaccine, according to routine immunization recommendations
Study: NCT02704130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial embolization
Description: In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
Study: NCT01194297

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: One dose of inactivated influenza vaccine, according to routine immunization recommendations
Study: NCT02238301

Intervention type: OTHER
Group type: OTHER
Intervention: Bold sequence patients test
Description: Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
Study: NCT02704130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
Study: NCT03030638

Intervention type: DRUG
Intervention: Olodaterol
Description: Drug

Intervention type: DRUG
Intervention: Indacaterol
Description: Drug
Study: NCT02215434

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Biolipid B2 (blanked/placebo)
Description: the intervention will be the comparison effects of both emulsions
Study: NCT02238301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bold + ASL sequence
Description: A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation.
Study: NCT02215434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biolipid B2 (blanked/placebo)
Description: the intervention will be the comparison effects of both emulsions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone, Transdermal, Behavior
Description: Transdermal 0.5% testosterone Biolipid/B2
Study: NCT02805192

Intervention type: DEVICE
Group type: OTHER
Intervention: Size Measurement by a Smart phone App
Study: NCT01903278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys /RBV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys /RBV
Study: NCT00812929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
Study: NCT02215434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone, Transdermal, Behavior
Description: Transdermal 0.5% testosterone Biolipid/B2
Study: NCT00812929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915
Description: This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
Study: NCT02287142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial plexus nerve block
Description: All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial plexus nerve block
Description: All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachial plexus nerve block
Description: All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
Study: NCT01544374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracking & Feedback
Description: Systems based intervention tracking oncology consultations and feeding back information to surgeons